$0.34
8.76% day before yesterday
Nasdaq, Dec 27, 10:18 pm CET
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Tonix Pharmaceuticals Holding Corp. Stock price

$0.34
+0.15 79.29% 1M
-0.35 51.07% 6M
-12.56 97.38% YTD
-12.94 97.46% 1Y
-2,506.54 99.99% 3Y
-7,068.46 100.00% 5Y
-40,959,999.66 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.03 8.76%
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Key metrics

Market capitalization $63.10m
Enterprise Value $43.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.86
P/S ratio (TTM) P/S ratio 5.59
P/B ratio (TTM) P/B ratio 0.71
Revenue growth (TTM) Revenue growth 183.05%
Revenue (TTM) Revenue $11.29m
EBIT (operating result TTM) EBIT $-82.59m
Free Cash Flow (TTM) Free Cash Flow $-69.19m
Cash position $28.23m
EPS (TTM) EPS $-20.56
P/E forward negative
P/S forward 4.93
EV/Sales forward 3.40
Short interest 5.48%
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Tonix Pharmaceuticals Holding Corp.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Tonix Pharmaceuticals Holding Corp.:

Buy
100%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
11 11
183% 183%
100%
- Direct Costs 13 13
123% 123%
118%
-2.06 -2.06
4% 4%
-18%
- Selling and Administrative Expenses 27 27
14% 14%
242%
- Research and Development Expense 49 49
48% 48%
432%
-78 -78
35% 35%
-693%
- Depreciation and Amortization 4.41 4.41
22% 22%
39%
EBIT (Operating Income) EBIT -83 -83
33% 33%
-732%
Net Profit -135 -135
12% 12%
-1,198%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Neutral
GlobeNewsWire
6 days ago
Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025
Positive
Invezz
12 days ago
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for TNX-102 SL, a non-opioid, centrally acting analgesic designed for fibromyalgia management.
Neutral
GlobeNewsWire
12 days ago
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 103
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today